by Sam Collins | May 17, 2012 2:30 am
Bristol-Myers Squibb (NYSE:BMY) — This leading drugmaker with a strong global emphasis in cardiovascular, anti-infective and anti-cancer therapeutics raised its dividend late last year to $1.36. The company has a long history of regular increases, and the latest brings its dividend yield to 4.11%. Although earnings are expected to decline to $1.95 this year vs. $2.16 in 2011 because of the expiration of patents, the company plans to expand its portfolio of drugs, and cost restructuring should help the bottom line.
The consensus price objective for 2012 is $38, which from the view of technical analysis appears achievable.
Source URL: http://investorplace.com/2012/05/a-big-trade-on-big-pharma-bmy/
Short URL: http://invstplc.com/1nA9CgP
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.